Capivasertib–fulvestrant is approved in Japan for the treatment of adult patients with unresectable or recurrent PIK3CA, AKT1 or PTEN-altered HR-positive/HER2-negative breast cancer following progression after treatment with endocrine therapy [20], and represents a novel treatment option for this patient population. This evidence concerns the gene ERBB2 and breast cancer.